Trends of pharmaceutical corporations’ external innovation strategies: An inverse sigmoid curve

Jianan Huang

Technology in Society, 2021, vol. 67, issue C

Abstract: For decades, scholars believe major pharmaceutical corporations have been facing a decline in R&D efficiency, leading to an increasing demand for early-stage (R&D stage) external innovation. However, after outlining pharmaceutical corporations’ demands on external innovation toolkits by an inverse sigmoid curve, this research indicates an increasing focus of major players on late-stage (commercial or late-development stage) external innovation. Initial results deliver a potential strategy that transferring external innovation focus in advance for R&D excellence, and also suggests policy-makers provide further platforms for enhancing external innovation ecosystem in the pharmaceutical industry.

Keywords: External research; Open innovation; Pharmaceutical industry; Technology management; Drug discovery (search for similar items in EconPapers)
Date: 2021
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (3)

Downloads: (external link)
http://www.sciencedirect.com/science/article/pii/S0160791X21002608
Full text for ScienceDirect subscribers only

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:eee:teinso:v:67:y:2021:i:c:s0160791x21002608

DOI: 10.1016/j.techsoc.2021.101785

Access Statistics for this article

Technology in Society is currently edited by Charla Griffy-Brown

More articles in Technology in Society from Elsevier
Bibliographic data for series maintained by Catherine Liu ().